Back to School: How biopharma can reboot drug development. Access exclusive analysis here
ABT's Kos Life Sciences Inc. subsidiary returned North American rights to Jerini's icatibant (see
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury